Table 1 Association of membrane EGFR localization with the clinical prognostic characteristics of the OC cohort
EGFR | ||||
|---|---|---|---|---|
M0 N (%) | M N (%) | MM N (%) | p-value | |
(N = 152) | (N = 145) | (N = 13) | ||
Age | ||||
< 65 | 105 (69.1%) | 104 (71.7%) | 11 (84.6%) | 0.522 |
> = 65 | 47 (30.9%) | 41 (28.3%) | 2 (15.4%) | |
Stadio (3 vs 4) | ||||
III | 119 (78.3%) | 120 (82.8%) | 11 (84.6%) | 0.611 |
IV | 33 (21.7%) | 25 (17.2%) | 2 (15.4%) | |
ECOG | ||||
0 | 120 (78.9%) | 117 (80.7%) | 11 (84.6%) | 0.938 |
1–2 | 32 (21.1%) | 28 (19.3%) | 2 (15.4%) | |
Tumor histology | ||||
HGSOC | 136 (89.5%) | 123 (84.8%) | 6 (46.2%) | < 0.001 |
Other | 16 (10.5%) | 22 (15.2%) | 7 (53.8%) | |
Residual | ||||
None | 66 (43.4%) | 58 (40.0%) | 7 (53.8%) | 0.787 |
< = 1 cm | 27 (17.8%) | 33 (22.8%) | 3 (23.1%) | |
> 1 cm | 49 (32.2%) | 45 (31.0%) | 2 (15.4%) | |
No surgery | 10 (6.6%) | 9 (6.2%) | 1 (7.7%) | |